Search Results
Jun 12, 2026, 02:10 ET Asia Bankers Club、TAKARA LEBENによる戦略的起用を受け、日本の不動産市場に進出
Kong形式：プレゼンテーションおよび質疑応答台北：日付：2026年6月11日時間およびセッション：午後6時30分場所：Oncor Membership Lounge（https://maps.app.goo.gl/Cd1BzPaR3huHq56k9?g_st=il）形式：プレゼンテーションおよびカクテルパーティー本プロジェクトで利用可能な外国人向け割当枠には限りがあるため、参加は完全予約制とし、先着順で受け付けます。Asia
More news about: Asia Bankers Club
Jun 11, 2026, 07:00 ET CD&R Engages Former Enovis CEO as Operating Advisor
June 11, 2026 /PRNewswire/ -- CD&R (or the "Firm") today announced that Matthew Trerotola, former Chief Executive Officer of Enovis Corporation, has been named an Operating Advisor to CD&R funds. In his new role, Matt will work closely with CD&R's healthcare and industrials investment
More news about: CD&R
Jun 11, 2026, 01:10 ET Se anuncian acuerdos de licencia y suministro de Zemcelpro® (terapia celular UM171) para Canadá
producto personalizado de trasplante de células madre hematopoyéticas criopreservadas que contiene dos componentes: células CD34+ expandidas con UM171 (dorocubicel) y células CD34- no expandidas, ambas derivadas de la misma unidad de sangre del cordón umbilical. El producto se utiliza para tratar neoplasias
More news about: ExCellThera
Jun 11, 2026, 01:06 ET Lizenz- und Liefervereinbarungen für Zemcelpro® (UM171-Zelltherapie) in Kanada bekannt gegeben
kryokonserviertes Produkt zur hämatopoetischen Stammzelltransplantation, das zwei Komponenten enthält, nämlich mit UM171 expandierte CD34+-Zellen (dorocubicel) sowie nicht expandierte CD34−-Zellen, die jeweils aus derselben Nabelschnurbluteinheit gewonnen werden. Das Produkt wird zur Behandlung von hämatologischen
More news about: ExCellThera
Jun 11, 2026, 00:15 ET Annonce des accords de licence et de fourniture de Zemcelpro® (thérapie cellulaire UM171) pour le Canada
personnalisé destiné à la greffe de cellules souches hématopoïétiques cryoconservées, composé de deux éléments : des cellules CD34+ multipliées par UM171 (dorocubicel) et des cellules CD34- non multipliées, toutes deux issues d'un même prélèvement de sang de cordon ombilical. Ce médicament est utilisé pour
More news about: ExCellThera
Jun 10, 2026, 15:01 ET Children's Hospital of Philadelphia Study May Help Explain Why Some Children with Sepsis or Organ Failure Face a Harder Recovery
toward real-time, biology-based treatments in the ICU."When the team examined immune cells, the sickest children had major disruption in CD8+ T cells, which normally help the body clear infections. These cells showed signs that they were being strongly activated by inflammation, but they
More news about: Children's Hospital of Philadelphia
Jun 10, 2026, 09:16 ET HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
evaluation and early developability confirmation. It is particularly applicable to siRNA and biologics targeting immune pathways such as BAFF, APRIL, CD40, OX40, TL1A, IL-17, IL-23, TSLP and FcRn.Conventional NHP Study vs. HkeyBio NHP Fast-PoC
More news about: HKeyBio
Jun 10, 2026, 08:03 ET Opsera Launches VIBEshift to Move AI-Generated Applications from Prototype to Production with a Single Command
autonomously, from provisioning infrastructure and configuring authentication to validating deployments and performing operational checks. It manages CI/CD tasks traditionally handled by multiple teams and tools.Key VIBEshift capabilities include:Autonomous Deployment: Automatically
More news about: Opsera
Jun 10, 2026, 07:45 ET Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The product is used to treat hematological malignancies (blood cancers), such
More news about: ExCellThera
Jun 10, 2026, 07:45 ET Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The product is used to treat hematological malignancies (blood cancers), such
More news about: ExCellThera
Jun 10, 2026, 04:23 ET Report of payments to government agencies 2025
https://mb.cision.com/Public/997/4359520/a45cd10e042e2fef.pdfPress release
More news about: Boliden
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
AG22515 is an investigational CD40L blocker being evaluated in CD40L mediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that binds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life. By blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is designed
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
AG22515 is an investigational CD40L blocker being evaluated in CD40L mediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that binds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life. By blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is designed
More news about: H. Lundbeck A/S
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Jun 09, 2026, 11:30 ET PolarX Reports More Hyper Grade Copper Assays as Northern Star Joint Venture Drilling commences at its Caribou Dome Copper Project in Alaska
drilling program has also commenced. With respect to the final assays from the 2025 diamond drilling program at Caribou Dome, exceptional assays from CD25-008 were 3.0m @ 11.23% Cu and 12.63 g/t Ag from 63.3 m. Additional, previously announced assays from the nine holes drilled in 2025 can be found here
More news about: PolarX Limited
Jun 09, 2026, 09:31 ET The Man Who Built Amazon Dynamo and Apache Cassandra Is Now Solving AI's Accountability Crisis
surprise liabilities at the end of the quarter.The Audit Is Coming. Can You Prove What Your AI Built?Git tracks who committed. CI/CD tracks what deployed. Neither tracks provenance -- whether a function was human-authored, AI-generated, which model produced it, under what authorization,
More news about: Weilliptic
Jun 09, 2026, 09:00 ET Sony Electronics Expands Professional Display Lineup with Crystal LED UNIFY, a 135-inch All-in-One Direct View Option
education spaces including boardrooms, meeting rooms, and community spaces. The cost-effective new model, which features a 1.5mm pixel pitch and 800 cd/m2 of maximum brightness, is expected to be available in early 2027. It is planned to be on display June 17-19, 2026, at InfoComm in Las Vegas at
More news about: Sony Electronics, Inc.
Jun 09, 2026, 09:00 ET Clovity Strengthens Executive Leadership Team with Strategic Appointments of Tyler Couch and Todd Nimigon
AI-powered, use-case-driven innovation, Clovity helps organizations modernize workflows, improve ITSM delivery, accelerate DevSecOps, and achieve CI/CD excellence. The company's ecosystem of apps and services empowers clients across federal, SLED, and enterprise verticals.Clovity is a five-time
More news about: Clovity
Jun 09, 2026, 08:37 ET David Armstrong Releases Historic Three-CD Collection Celebrating All 50 States for America's 250th Anniversary
2026, independent recording artist and Heartwave creator David Armstrong has completed an ambitious musical project unlike any other: a three-CD collection featuring an original song dedicated to each of the fifty states. Titled "My Country 'Tis of Thee" Volumes 1, 2, and 3, the
More news about: David Armstrong
Jun 09, 2026, 08:34 ET Exavalu Launches ExAite™, an Agentic AI Platform Redefining Quality Engineering from Requirements to Release
deliver more relevant and accurate testing outcomes.Built for modern engineering ecosystems, ExAitetm integrates seamlessly with CI/CD pipelines, supporting scalable continuous testing, AI-orchestrated execution, and real-time reporting. With stable, flake-free test execution, teams
More news about: Exavalu
Jun 09, 2026, 03:20 ET [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
precision radiodiagnostics and -therapeutics in oncology and cardiology, anchored in CXCR4-targeted PET/CT programs. The pipeline is complemented by a CD24-based next-generation antibody platform and a reliable isotope supply network.Contact Investor Relations & Media
More news about: Pentixapharm Holding AG
Jun 09, 2026, 03:10 ET Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised
More news about: Pentixapharm Holding AG
Jun 08, 2026, 09:14 ET Doppler Brings Secrets Management On-prem for Full Control
best practices without slowing teams down. Security professionals gain audit logs, anomaly detection, and compliance tools, while DevOps automates CI/CD syncs, infrastructure integrations, and secret versioning. Protect data, prevent leaks, and ensure reliability so teams can focus on innovation, not
More news about: Doppler
Jun 08, 2026, 09:00 ET Energration and Atombeam Submit DARPA Proposal to Advance Mission-Ready Tactical Data Movement
contract awards and demonstrated delivery at every AACE classification level (Class 5 through Class 1) and every DOE Critical Decision gate (CD-0 through CD-4). Online at
More news about: Atombeam
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy
More news about: AbbVie